Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705290 | 0.84 | KIF11 (0.38) | KIF11CYP11B2CYP11B1GPR3SMN1; SMN2 | |
| SCHEMBL12829126 | 0.82 | GPR3 (0.38) | KIF11CYP11B2CYP11B1GPR3SMN1; SMN2 | |
| SCHEMBL17705292 | 0.80 | TSHR (0.35) | KIF11ACHENFE2L2 | |
| SCHEMBL18265626 | 0.79 | KIF11 (0.35) | KIF11CYP11B2CYP11B1GPR3SMN1; SMN2 | |
| SCHEMBL12829127 | 0.79 | KIF11 (0.35) | KIF11CYP11B2CYP11B1GPR3SMN1; SMN2 | |
| SCHEMBL12829129 | 0.77 | GPR3 (0.38) | KIF11CYP11B2CYP11B1GPR3 | |
| SCHEMBL6470423 | 0.77 | KIF11 (0.42) | KIF11CYP11B2CYP11B1GPR3SMN1; SMN2 | |
| SCHEMBL15773593 | 0.77 | CYP11B1 (0.35) | KIF11CYP11B2CYP11B1GPR3 | |
| SCHEMBL14749514 | 0.75 | FFAR4 (0.34) | KIF11FFAR4 | |
| SCHEMBL15318779 | 0.74 | KIF11 (0.33) | KIF11CYP11B2CYP11B1GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822305-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9809749-B2 | Mesogenic compound, liquid-crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9593279-B2 | Liquid-crystalline medium and high-frequency components comprising same | MERCK PATENT GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | BMP2, IK, EML4 | KIF11 119/4885CYP11B2 2330/4885CYP11B1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.